Compare ARK Genomic Revolution ETF (ARKG) vs Futu Holdings Ltd (FUTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Futu Holdings Ltd — how do they compare? ARK Genomic Revolution ETF trades at $44.62, while Futu Holdings Ltd trades at $105.19 (market cap $14.74B). The key difference: Futu Holdings Ltd pays a 2.47% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Futu Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| ARKG | FUTU | |
|---|---|---|
Sector | Sector/Thematic | Financials |
52-Week High | $44.55 | $199.04 |
52-Week Low | $24.02 | $89.76 |
Market Cap | — | $14.74B |
Enterprise Value | — | $14.59B |
Dividend Yield | — | 2.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $44.49, up 0.41% today, with a bullish technical bias from moving averages but overbought RSI signals. The ETF focuses on genomic revolution stocks, with top 10 holdings comprising 59% of assets and a long-term EPS growth rate of 10.7% (Seeking Alpha, 2026-07-28). Recent news highlights biotech sector strength driven by FDA friendliness and AI-driven drug discovery.
Outlook is cautiously optimistic given sector tailwinds, but high concentration and volatility pose risks. The ETF's exposure to small- and mid-cap biotech offers growth potential, yet investors face regulatory and market sentiment shifts. Near-term performance may hinge on broader tech trends and biotech M&A activity.
FUTU trades at $105.41, down 3.03% today, amid a securities class action filing alleging regulatory compliance failures. The stock shows strong fundamentals with a P/E of 11.63 and net income margin of 41.83%, supported by robust revenue growth from $13.6B in 2024 to $22.85B in 2025. Technical indicators are bullish on moving averages, with key support at $103 and resistance at $110.
The outlook is mixed: strong profitability and analyst consensus (58% buy ratings) support upside, but legal risks and recent earnings misses pose significant headwinds. Investors should weigh solid financials against litigation overhang and market sentiment pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →
